Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Vincent Ciuryla"'
Publikováno v:
Vaccine. 27:4694-4703
We developed an age-structured, transmission-dynamic, mathematical model to quantify the direct and indirect benefits of infant PCV7 vaccination. The model simulates the acquisition of asymptomatic carriage of Streptococcus pneumoniae and the develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a944b4866daf75a2d81d56092e69d874
https://doi.org/10.1016/j.vaccine.2009.05.062
https://doi.org/10.1016/j.vaccine.2009.05.062
The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine
Autor:
N. Horowicz-Mehler, David R. Strutton, Roman Casciano, Lee Stern, Daniel J. Isaacman, Edward A. Kalpas, Vincent Ciuryla
Publikováno v:
Clinical Therapeutics. 30:341-357
The heptavalent pneumococcal polysaccharide-protein conjugate vaccine (PCV7) confers protection against invasive pneumococcal disease (IPD) caused by serotypes that are responsible for substantial morbidity and mortality throughout the world. In 2000
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1aff38865e921b66eed6132049805a7c
https://doi.org/10.1016/j.clinthera.2008.02.003
https://doi.org/10.1016/j.clinthera.2008.02.003
Publikováno v:
Vaccine. 25:2420-2427
Prevnar (heptavalent pneumococcal conjugate vaccine; PCV7) provides protection against invasive pneumococcal disease (IPD) caused by vaccine serotypes. Indirect protection of non-immunised individuals may be the consequence of decreased transmission
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ca7b050df2553849075aca564b11dd3
https://doi.org/10.1016/j.vaccine.2006.09.011
https://doi.org/10.1016/j.vaccine.2006.09.011
Publikováno v:
Pediatric Infectious Disease Journal. 25:494-501
Pneumococcal conjugate vaccine (PCV) has been in routine use in the United States for 5 years. Prior U.S. cost-effectiveness analyses have not taken into account the effect of the vaccine on nonvaccinated persons.We revised a previously published mod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1ed6e1638b2ebf88f07211329031112
https://doi.org/10.1097/01.inf.0000222403.42974.8b
https://doi.org/10.1097/01.inf.0000222403.42974.8b
Autor:
Gerry Oster, Derek Weycker, Vincent Ciuryla, John Edelsberg, Ira M. Longini, Azhar Nizam, M. Elizabeth Halloran
Publikováno v:
Vaccine. 23:1284-1293
Using a stochastic simulation model of influenza transmission, clinical illness, and economic costs, we estimated the population-wide benefits of routinely vaccinating US children (ages 6 months to 18 years) against influenza. Disease burden was proj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::365c068d120bb398c1ddf098d1045937
https://doi.org/10.1016/j.vaccine.2004.08.044
https://doi.org/10.1016/j.vaccine.2004.08.044
Autor:
James D. Kellner, Kyle Hvidsten, Edward C Y Wang, Vincent Ciuryla, E. Lee Ford-Jones, Steven R. Arikian, Roman Casciano, Marc H. Lebel
Publikováno v:
Clinical Infectious Diseases. 36:259-268
The objective of this study was to evaluate the projected health benefits, costs, and cost-effectiveness of pneumococcal conjugate vaccination for infants and children aged
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec90a9562d4365f27bcb97c3513eaa05
https://doi.org/10.1086/345833
https://doi.org/10.1086/345833
Autor:
Gerry Oster, Derek Weycker, David R. Strutton, Jerome O. Klein, Stephen I. Pelton, Vincent Ciuryla
Publikováno v:
Vaccine. 28(6)
Background Immunogenicity studies suggest antibody responses from a 7-valent pneumococcal conjugate vaccine (PCV7) regimen consisting of 2 doses in the primary series are less immunogenic, for at least several vaccine serotypes, compared with a regim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f53940b3eff756e6a963cf3b7d7e5a1
https://pubmed.ncbi.nlm.nih.gov/20003928
https://pubmed.ncbi.nlm.nih.gov/20003928
Publikováno v:
PharmacoEconomics. 22(5)
Objective: To determine the impact of respiratory syncytial virus (RSV) infection on healthcare resource use and costs in the US from the third-party payer perspective. Design: The study retrospectively analysed cross-sectional medical encounter data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59dc37d05fdfc70aaad3d50184c14032
https://pubmed.ncbi.nlm.nih.gov/15061677
https://pubmed.ncbi.nlm.nih.gov/15061677
Publikováno v:
Value in Health. 3(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41af2431496192daae1a7172e4a9031c
Publikováno v:
Value in Health. 3:121-122
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fa15d498e72e056679db9238b72e21e
https://doi.org/10.1016/s1098-3015(11)70506-x
https://doi.org/10.1016/s1098-3015(11)70506-x